Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers
On November 21, 2016, our board of directors appointed Dr. Edward
J. Benz to serve as a member of our board of directors. Dr. Benz
is a renowned expert in blood disorders and is board certified in
both hematology and internal medicine. He is an active clinical
hematologist and a National Institutes of Health (NIH) funded
researcher with a focus on the molecular basis and genetics
around inherited blood disorders. Since November 2000, Dr. Benz
has served as President and CEO of Dana-Faber Cancer Institute
and the Richard and Susan Smith Professor of Medicine and
Professor of Genetics at Harvard Medical School. Prior to his
role at Dana-Faber, Dr. Benz served as the chairman for the
Department of Medicine and Sir William Osler Professor of
Medicine at Johns Hopkins University School of Medicine, as well
as physician in chief at Johns Hopkins Hospital. Dr. Benz has
also served as President of the American Society of Hematology,
the Association of American Cancer Institutes, the American
Society for Clinical Investigation, the American Clinical and
Climatological Society, and the Friends of the National Institute
of Nursing Research. Over the course of his career, Dr. Benz has
authored more than 300 articles, books, reviews and abstracts and
has received numerous awards.
There are no family relationships between Dr. Benz and any of our
current directors or executive officers. A copy of Dr. Benzs
directors letter agreement is attached hereto as Exhibit 10.1.
Dr. Benz has not had any material direct or indirect interest in
any of our transactions or proposed transactions over the last
two years. At this time, we do not have an employment agreement
with Dr. Benz but have entered into a letter arrangement dated
November 18, 2016 regarding his involvement on the board of
directors.
SECTION 7 Regulation FD
Item 7.01 Regulation FD Disclosure
In addition to disclosing current information to Section 13 or
15(d) of the Securities Exchange Act of 1934 and for reports of
information required to be disclosed by Regulation FD through our
SEC filings, we also intend to disclose such current information
through our investor relations website, press releases, public
conference calls, webcasts and through the following social media
channels:
|
Xenetic Biosciences, Inc.s Facebook Page (https://www.facebook.com/xeneticbio) |
|
Xenetic Biosciences, Inc.s Twitter (https://twitter.com/XeneticBio) |
|
Xenetic Biosciences, Inc.s LinkedIn Page (https://www.linkedin.com/company/xenetic-biosciences-inc-) |
| Xenetic Biosciences, Inc.s Google Page |
(https://plus.google.com/103621858654196899741/about)
| Xenetic Biosciences, Inc.s Chairmans Blog Profile |
(http://www.thechairmansblog.com/xenetic-biosciences)
SECTION 8 OTHER EVENTS
Item 8.01 Other Events
On November 22, 2016, we issued a press release announcing the
appointment of Dr. Benz.
A copy of the Press Release is attached hereto as Exhibit 99.1.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01 Financial Statement and Exhibits
| Exhibit No. | Description |
|
10.1 |
Directors Letter Agreement |
| 99.1 | Press Release |
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII. Xenetic Biosciences, Inc. (NASDAQ:XBIO) Recent Trading Information
Xenetic Biosciences, Inc. (NASDAQ:XBIO) closed its last trading session down -0.19 at 3.41 with 2,389 shares trading hands.
